Hepatocellular Carcinoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Hepatocellular Carcinoma – Pipeline Review, H2 2016’, provides an overview of the Hepatocellular Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma

The report reviews pipeline therapeutics for Hepatocellular Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hepatocellular Carcinoma therapeutics and enlists all their major and minor projects

The report assesses Hepatocellular Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Hepatocellular Carcinoma – Companies Involved in Therapeutics D

4SC AG

AB Science SA

Acceleron Pharma Inc

ACROVIS Pharma AG

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

Alfact Innovation

Amgen Inc

AndroScience Corp

ArQule Inc

Array BioPharma Inc

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Bio-Cancer Treatment International Ltd

Bioneer Corp

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Can-Fite BioPharma Ltd

CASI Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Celsion Corp

China Medical System Holdings Ltd

Chroma Therapeutics Ltd

Chugai Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

Delcath Systems Inc

Dicerna Pharmaceuticals Inc

Double Bond Pharmaceutical International AB

Eisai Co Ltd

Eli Lilly and Company

Endocyte Inc

Epeius Biotechnologies Corp

eTheRNA Immunotherapies NV

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Galaxy Biotech LLC

Genelux Corp

Genoscience Pharma

Genosco

Gilead Sciences Inc

GlaxoSmithKline Plc

Golden Biotechnology Corp

Green Cross Cell Corp

Green Cross Corp

H3 Biomedicine Inc

HanAll Biopharma Co Ltd

HEC Pharm Co., Ltd.

Horizon Pharma Plc

Immune Therapeutics, Inc.

Immunicum AB

Immunitor Inc

Immunomedics Inc

Immunovative Therapies Ltd

In-Cell-Art SAS

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

InteRNA Technologies BV

Jenrin Discovery Inc

Johnson & Johnson

KAHR medical Ltd

Karcinolys SAS

Kite Pharma Inc

Komipharm International Co Ltd

Kowa Company Ltd

Les Laboratoires Servier SAS

Ligand Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

MaxCyte Inc

MedImmune LLC

Medivation Inc

Medivir AB

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

Mina Therapeutics Ltd

Molecular Partners AG

MolMed SpA

MultiCell Technologies Inc

NormOxys Inc

Novartis AG

NovaTarg Therapeutics Inc

Nymox Pharmaceutical Corp

Omeros Corp

Oncolys BioPharma Inc

OncoMed Pharmaceuticals Inc

OncoTherapy Science Inc

Oneness Biotech Co Ltd

Ono Pharmaceutical Co Ltd

Onxeo SA

Otsuka Holdings Co Ltd

Panacea Pharmaceuticals Inc

PepVax Inc

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

PharmaEssentia Corp

Provecs Medical GmbH

Provectus Biopharmaceuticals Inc

RedHill Biopharma Ltd

Regulus Therapeutics Inc

Rigontec GmbH

Saronic Biotechnology Inc

Shenogen Pharma Group Ltd

Shenzen SiBiono GeneTech Co., Ltd.

Sillajen Biotherapeutics

Taiwan Liposome Company Ltd

Tara Immuno-Oncology Therapeutics LLC

TC BioPharm Ltd

Tessa Therapeutics Pte Ltd

Therapure Biopharma Inc

Theravectys SA

Threshold Pharmaceuticals Inc

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Tumorend LLC

UbiVac LLC

VasGene Therapeutics Inc

Vaxon Biotech

Vect-Horus SAS

Verlyx Pharma Inc

Vicus Therapeutics LLC

Virttu Biologics Ltd

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Hepatocellular Carcinoma Overview 9

Therapeutics Development 10

Hepatocellular Carcinoma - Therapeutics under Development by Companies 12

Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes 22

Hepatocellular Carcinoma - Pipeline Products Glance 24

Hepatocellular Carcinoma - Products under Development by Companies 27

Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes 42

Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 44

Hepatocellular Carcinoma - Therapeutics Assessment 178

Drug Profiles 206

Hepatocellular Carcinoma - Dormant Projects 900

Hepatocellular Carcinoma - Discontinued Products 911

Hepatocellular Carcinoma - Product Development Milestones 915

Appendix 933

List of Tables

List of Tables

Number of Products under Development for Hepatocellular Carcinoma, H2 2016 36

Number of Products under Development for Hepatocellular Carcinoma – Comparative Analysis, H2 2016 37

Number of Products under Development by Companies, H2 2016 38

Number of Products under Development by Companies, H2 2016 (Contd..1) 39

Number of Products under Development by Companies, H2 2016 (Contd..2) 40

Number of Products under Development by Companies, H2 2016 (Contd..3) 41

Number of Products under Development by Companies, H2 2016 (Contd..4) 42

Number of Products under Development by Companies, H2 2016 (Contd..5) 43

Number of Products under Development by Companies, H2 2016 (Contd..6) 44

Number of Products under Development by Companies, H2 2016 (Contd..7) 45

Number of Products under Development by Companies, H2 2016 (Contd..8) 46

Number of Products under Development by Companies, H2 2016 (Contd..9) 47

Number of Products under Investigation by Universities/Institutes, H2 2016 48

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 49

Comparative Analysis by Late Stage Development, H2 2016 50

Comparative Analysis by Clinical Stage Development, H2 2016 51

Comparative Analysis by Early Stage Development, H2 2016 52

Products under Development by Companies, H2 2016 53

Products under Development by Companies, H2 2016 (Contd..1) 54

Products under Development by Companies, H2 2016 (Contd..2) 55

Products under Development by Companies, H2 2016 (Contd..3) 56

Products under Development by Companies, H2 2016 (Contd..4) 57

Products under Development by Companies, H2 2016 (Contd..5) 58

Products under Development by Companies, H2 2016 (Contd..6) 59

Products under Development by Companies, H2 2016 (Contd..7) 60

Products under Development by Companies, H2 2016 (Contd..8) 61

Products under Development by Companies, H2 2016 (Contd..9) 62

Products under Development by Companies, H2 2016 (Contd..10) 63

Products under Development by Companies, H2 2016 (Contd..11) 64

Products under Development by Companies, H2 2016 (Contd..12) 65

Products under Development by Companies, H2 2016 (Contd..13) 66

Products under Development by Companies, H2 2016 (Contd..14) 67

Products under Investigation by Universities/Institutes, H2 2016 68

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 69

Hepatocellular Carcinoma – Pipeline by 4SC AG, H2 2016 70

Hepatocellular Carcinoma – Pipeline by AB Science SA, H2 2016 71

Hepatocellular Carcinoma – Pipeline by Acceleron Pharma Inc, H2 2016 72

Hepatocellular Carcinoma – Pipeline by ACROVIS Pharma AG, H2 2016 73

Hepatocellular Carcinoma – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 74

Hepatocellular Carcinoma – Pipeline by Advenchen Laboratories LLC, H2 2016 75

Hepatocellular Carcinoma – Pipeline by Alfact Innovation, H2 2016 76

Hepatocellular Carcinoma – Pipeline by Amgen Inc, H2 2016 77

Hepatocellular Carcinoma – Pipeline by AndroScience Corp, H2 2016 78

Hepatocellular Carcinoma – Pipeline by ArQule Inc, H2 2016 79

Hepatocellular Carcinoma – Pipeline by Array BioPharma Inc, H2 2016 80

Hepatocellular Carcinoma – Pipeline by Astellas Pharma Inc, H2 2016 81

Hepatocellular Carcinoma – Pipeline by Astex Pharmaceuticals Inc, H2 2016 82

Hepatocellular Carcinoma – Pipeline by AstraZeneca Plc, H2 2016 83

Hepatocellular Carcinoma – Pipeline by AVEO Pharmaceuticals Inc, H2 2016 84

Hepatocellular Carcinoma – Pipeline by Bayer AG, H2 2016 85

Hepatocellular Carcinoma – Pipeline by BeiGene Ltd, H2 2016 86

Hepatocellular Carcinoma – Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 87

Hepatocellular Carcinoma – Pipeline by Bioneer Corp, H2 2016 88

Hepatocellular Carcinoma – Pipeline by Blueprint Medicines Corp, H2 2016 89

Hepatocellular Carcinoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 90

Hepatocellular Carcinoma – Pipeline by Boston Biomedical Inc, H2 2016 91

Hepatocellular Carcinoma – Pipeline by Bristol-Myers Squibb Company, H2 2016 92

Hepatocellular Carcinoma – Pipeline by Can-Fite BioPharma Ltd, H2 2016 93

Hepatocellular Carcinoma – Pipeline by CASI Pharmaceuticals Inc, H2 2016 94

Hepatocellular Carcinoma – Pipeline by CCRP Therapeutics GmbH, H2 2016 95

Hepatocellular Carcinoma – Pipeline by Celgene Corp, H2 2016 96

Hepatocellular Carcinoma – Pipeline by Celldex Therapeutics Inc, H2 2016 97

Hepatocellular Carcinoma – Pipeline by Celsion Corp, H2 2016 98

Hepatocellular Carcinoma – Pipeline by China Medical System Holdings Ltd, H2 2016 99

Hepatocellular Carcinoma – Pipeline by Chroma Therapeutics Ltd, H2 2016 100

Hepatocellular Carcinoma – Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 101

Hepatocellular Carcinoma – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 102

Hepatocellular Carcinoma – Pipeline by Delcath Systems Inc, H2 2016 103

Hepatocellular Carcinoma – Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 104

Hepatocellular Carcinoma – Pipeline by Double Bond Pharmaceutical International AB, H2 2016 105

Hepatocellular Carcinoma – Pipeline by Eisai Co Ltd, H2 2016 106

Hepatocellular Carcinoma – Pipeline by Eli Lilly and Company, H2 2016 107

Hepatocellular Carcinoma – Pipeline by Endocyte Inc, H2 2016 108

Hepatocellular Carcinoma – Pipeline by Epeius Biotechnologies Corp, H2 2016 109

Hepatocellular Carcinoma – Pipeline by eTheRNA Immunotherapies NV, H2 2016 110

Hepatocellular Carcinoma – Pipeline by Exelixis Inc, H2 2016 111

Hepatocellular Carcinoma – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 112

Hepatocellular Carcinoma – Pipeline by Faron Pharmaceuticals Oy, H2 2016 113

Hepatocellular Carcinoma – Pipeline by Galaxy Biotech LLC, H2 2016 114

Hepatocellular Carcinoma – Pipeline by Genelux Corp, H2 2016 115

Hepatocellular Carcinoma – Pipeline by Genoscience Pharma, H2 2016 116

Hepatocellular Carcinoma – Pipeline by Genosco, H2 2016 117

Hepatocellular Carcinoma – Pipeline by Gilead Sciences Inc, H2 2016 118

Hepatocellular Carcinoma – Pipeline by GlaxoSmithKline Plc, H2 2016 119

Hepatocellular Carcinoma – Pipeline by Golden Biotechnology Corp, H2 2016 120

Hepatocellular Carcinoma – Pipeline by Green Cross Cell Corp, H2 2016 121

Hepatocellular Carcinoma – Pipeline by Green Cross Corp, H2 2016 122

Hepatocellular Carcinoma – Pipeline by H3 Biomedicine Inc, H2 2016 123

Hepatocellular Carcinoma – Pipeline by HanAll Biopharma Co Ltd, H2 2016 124

Hepatocellular Carcinoma – Pipeline by HEC Pharm Co., Ltd., H2 2016 125

Hepatocellular Carcinoma – Pipeline by Horizon Pharma Plc, H2 2016 126

Hepatocellular Carcinoma – Pipeline by Immune Therapeutics, Inc., H2 2016 127

Hepatocellular Carcinoma – Pipeline by Immunicum AB, H2 2016 128

Hepatocellular Carcinoma – Pipeline by Immunitor Inc, H2 2016 129

Hepatocellular Carcinoma – Pipeline by Immunomedics Inc, H2 2016 130

Hepatocellular Carcinoma – Pipeline by Immunovative Therapies Ltd, H2 2016 131

Hepatocellular Carcinoma – Pipeline by In-Cell-Art SAS, H2 2016 132

Hepatocellular Carcinoma – Pipeline by Inovio Pharmaceuticals Inc, H2 2016 133

Hepatocellular Carcinoma – Pipeline by Inspyr Therapeutics Inc, H2 2016 134

Hepatocellular Carcinoma – Pipeline by InteRNA Technologies BV, H2 2016 135

Hepatocellular Carcinoma – Pipeline by Jenrin Discovery Inc, H2 2016 136

Hepatocellular Carcinoma – Pipeline by Johnson & Johnson, H2 2016 137

Hepatocellular Carcinoma – Pipeline by KAHR medical Ltd, H2 2016 138

Hepatocellular Carcinoma – Pipeline by Karcinolys SAS, H2 2016 139

Hepatocellular Carcinoma – Pipeline by Kite Pharma Inc, H2 2016 140

Hepatocellular Carcinoma – Pipeline by Komipharm International Co Ltd, H2 2016 141

Hepatocellular Carcinoma – Pipeline by Kowa Company Ltd, H2 2016 142

Hepatocellular Carcinoma – Pipeline by Les Laboratoires Servier SAS, H2 2016 143

Hepatocellular Carcinoma – Pipeline by Ligand Pharmaceuticals Inc, H2 2016 144

Hepatocellular Carcinoma – Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 145

Hepatocellular Carcinoma – Pipeline by MaxCyte Inc, H2 2016 146

Hepatocellular Carcinoma – Pipeline by MedImmune LLC, H2 2016 147

Hepatocellular Carcinoma – Pipeline by Medivation Inc, H2 2016 148

Hepatocellular Carcinoma – Pipeline by Medivir AB, H2 2016 149

Hepatocellular Carcinoma – Pipeline by Merck & Co Inc, H2 2016 150

Hepatocellular Carcinoma – Pipeline by Merck KGaA, H2 2016 151

Hepatocellular Carcinoma – Pipeline by Merrimack Pharmaceuticals Inc, H2 2016 152

Hepatocellular Carcinoma – Pipeline by Midatech Pharma Plc, H2 2016 153

Hepatocellular Carcinoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 154

Hepatocellular Carcinoma – Pipeline by Mina Therapeutics Ltd, H2 2016 155

Hepatocellular Carcinoma – Pipeline by Molecular Partners AG, H2 2016 156

Hepatocellular Carcinoma – Pipeline by MolMed SpA, H2 2016 157

Hepatocellular Carcinoma – Pipeline by MultiCell Technologies Inc, H2 2016 158

Hepatocellular Carcinoma – Pipeline by NormOxys Inc, H2 2016 159

Hepatocellular Carcinoma – Pipeline by Novartis AG, H2 2016 160

Hepatocellular Carcinoma – Pipeline by NovaTarg Therapeutics Inc, H2 2016 161

Hepatocellular Carcinoma – Pipeline by Nymox Pharmaceutical Corp, H2 2016 162

Hepatocellular Carcinoma – Pipeline by Omeros Corp, H2 2016 163

Hepatocellular Carcinoma – Pipeline by Oncolys BioPharma Inc, H2 2016 164

Hepatocellular Carcinoma – Pipeline by OncoMed Pharmaceuticals Inc, H2 2016 165

Hepatocellular Carcinoma – Pipeline by OncoTherapy Science Inc, H2 2016 166

Hepatocellular Carcinoma – Pipeline by Oneness Biotech Co Ltd, H2 2016 167

Hepatocellular Carcinoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 168

Hepatocellular Carcinoma – Pipeline by Onxeo SA, H2 2016 169

Hepatocellular Carcinoma – Pipeline by Otsuka Holdings Co Ltd, H2 2016 170

Hepatocellular Carcinoma – Pipeline by Panacea Pharmaceuticals Inc, H2 2016 171

Hepatocellular Carcinoma – Pipeline by PepVax Inc, H2 2016 172

Hepatocellular Carcinoma – Pipeline by Pfizer Inc, H2 2016 173

Hepatocellular Carcinoma – Pipeline by Pharma Mar SA, H2 2016 174

Hepatocellular Carcinoma – Pipeline by PharmAbcine Inc, H2 2016 175

Hepatocellular Carcinoma – Pipeline by PharmaEssentia Corp, H2 2016 176

Hepatocellular Carcinoma – Pipeline by Provecs Medical GmbH, H2 2016 177

Hepatocellular Carcinoma – Pipeline by Provectus Biopharmaceuticals Inc, H2 2016 178

Hepatocellular Carcinoma – Pipeline by RedHill Biopharma Ltd, H2 2016 179

Hepatocellular Carcinoma – Pipeline by Regulus Therapeutics Inc, H2 2016 180

Hepatocellular Carcinoma – Pipeline by Rigontec GmbH, H2 2016 181

Hepatocellular Carcinoma – Pipeline by Saronic Biotechnology Inc, H2 2016 182

Hepatocellular Carcinoma – Pipeline by Shenogen Pharma Group Ltd, H2 2016 183

Hepatocellular Carcinoma – Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016 184

Hepatocellular Carcinoma – Pipeline by Sillajen Biotherapeutics, H2 2016 185

Hepatocellular Carcinoma – Pipeline by Taiwan Liposome Company Ltd, H2 2016 186

Hepatocellular Carcinoma – Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016 187

Hepatocellular Carcinoma – Pipeline by TC BioPharm Ltd, H2 2016 188

Hepatocellular Carcinoma – Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 189

Hepatocellular Carcinoma – Pipeline by Therapure Biopharma Inc, H2 2016 190

Hepatocellular Carcinoma – Pipeline by Theravectys SA, H2 2016 191

Hepatocellular Carcinoma – Pipeline by Threshold Pharmaceuticals Inc, H2 2016 192

Hepatocellular Carcinoma – Pipeline by Tiziana Life Sciences Plc, H2 2016 193

Hepatocellular Carcinoma – Pipeline by TRACON Pharmaceuticals Inc, H2 2016 194

Hepatocellular Carcinoma – Pipeline by Tumorend LLC, H2 2016 195

Hepatocellular Carcinoma – Pipeline by UbiVac LLC, H2 2016 196

Hepatocellular Carcinoma – Pipeline by VasGene Therapeutics Inc, H2 2016 197

Hepatocellular Carcinoma – Pipeline by Vaxon Biotech, H2 2016 198

Hepatocellular Carcinoma – Pipeline by Vect-Horus SAS, H2 2016 199

Hepatocellular Carcinoma – Pipeline by Verlyx Pharma Inc, H2 2016 200

Hepatocellular Carcinoma – Pipeline by Vicus Therapeutics LLC, H2 2016 201

Hepatocellular Carcinoma – Pipeline by Virttu Biologics Ltd, H2 2016 202

Hepatocellular Carcinoma – Pipeline by Vyriad Inc, H2 2016 203

Assessment by Monotherapy Products, H2 2016 204

Assessment by Combination Products, H2 2016 205

Number of Products by Stage and Target, H2 2016 207

Number of Products by Stage and Mechanism of Action, H2 2016 218

Number of Products by Stage and Route of Administration, H2 2016 229

Number of Products by Stage and Molecule Type, H2 2016 231

Hepatocellular Carcinoma – Dormant Projects, H2 2016 926

Hepatocellular Carcinoma – Dormant Projects (Contd..1), H2 2016 927

Hepatocellular Carcinoma – Dormant Projects (Contd..2), H2 2016 928

Hepatocellular Carcinoma – Dormant Projects (Contd..3), H2 2016 929

Hepatocellular Carcinoma – Dormant Projects (Contd..4), H2 2016 930

Hepatocellular Carcinoma – Dormant Projects (Contd..5), H2 2016 931

Hepatocellular Carcinoma – Dormant Projects (Contd..6), H2 2016 932

Hepatocellular Carcinoma – Dormant Projects (Contd..7), H2 2016 933

Hepatocellular Carcinoma – Dormant Projects (Contd..8), H2 2016 934

Hepatocellular Carcinoma – Dormant Projects (Contd..9), H2 2016 935

Hepatocellular Carcinoma – Dormant Projects (Contd..10), H2 2016 936

Hepatocellular Carcinoma – Discontinued Products, H2 2016 937

Hepatocellular Carcinoma – Discontinued Products (Contd..1), H2 2016 938

Hepatocellular Carcinoma – Discontinued Products (Contd..2), H2 2016 939

Hepatocellular Carcinoma – Discontinued Products (Contd..3), H2 2016 940

List of Figures

List of Figures

Number of Products under Development for Hepatocellular Carcinoma, H2 2016 36

Number of Products under Development for Hepatocellular Carcinoma – Comparative Analysis, H2 2016 37

Number of Products under Development by Companies, H2 2016 38

Number of Products under Investigation by Universities/Institutes, H2 2016 48

Comparative Analysis by Late Stage Development, H2 2016 50

Comparative Analysis by Clinical Stage Development, H2 2016 51

Comparative Analysis by Early Stage Products, H2 2016 52

Assessment by Monotherapy Products, H2 2016 204

Assessment by Combination Products, H2 2016 205

Number of Products by Top 10 Targets, H2 2016 206

Number of Products by Stage and Top 10 Targets, H2 2016 206

Number of Products by Top 10 Mechanism of Actions, H2 2016 217

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 217

Number of Products by Top 10 Routes of Administration, H2 2016 228

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 228

Number of Products by Top 10 Molecule Types, H2 2016 230

Number of Products by Stage and Top 10 Molecule Types, H2 2016 230

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports